About our Trials

Our clinical and research trials create medically important data that tests how well SM-88 works in patients. Our studies are designed to answer scientific questions and the needs of the patients. Tyme Inc. is constantly seeking better ways to treat all types of cancers. Our studies are designed to test our drug as a monotherapy and in combination platforms. Tyme runs trials in parallel with traditional lines of treatment to create comparative analysis. When trials are complete, our goal is to provide our results to all the appropriate regulatory agencies, healthcare providers, people with cancer and the public. Every clinical trial has a well-defined protocol, and/or action plan. The protocol describes an overview of the study, the science behind the mechanism of action, how the study will be conducted, and why a particular indication was chosen. Each study has an inclusion and exclusion criteria which defines who can participate. Some cancer indications studies do require recruiting volunteers. All protocol designed studies are approved by Institutional Review Board (IRB- is an independent committee of physicians, statisticians, and members of the community), monitors, and the FDA.

Our primary goal is to:

  • Define the efficacy of SM-88
  • Protect the rights and welfare of the participants
  • Define the risks and make sure they are reasonable when compared to conventional treatments

(In the United States, a clinical trial must have an IRB if it is studying a drug, biological product, or medical device that the Food and Drug Administration (FDA) regulates, or it is funded or carried out by the federal government).

clinicaltrial
clinicaltrialiamge2
clinicaltrialimage3

Tyme is recruiting patients for the following Clinical Trial:

Study of the Optimum Dose, Safety, Efficacy of SM-88 in Patients With Metastatic Pancreatic Cancer

Conditions: Pancreatic Cancer; Metastatic, Previously Treated

CURRENTLY ENROLLING LOCATIONS ARE LISTED BELOW

Additional trial information can be found here (www.clinicaltrials.gov)

SETAUKET CANCER
RESEARCH CENTER

East Setauket, NY 11733

SARCOMA ONCOLOGY
RESEARCH CENTER

Santa Monica, CA 09403

CENTER FOR CANCER
AND BLOOD DISORDERS

Fort Worth, TX 76104

CANCER CENTER OF CENTRAL
CONNECTICUT - SOUTHINGTON

Southington, CT 06489

VIRGINA MASON
MEDICAL CENTER

Seattle, WA 98101

FLORIDA HOSPITAL-
TAMPA

Tampa, FL 33613

NEW YORK CANCER
AND BLOOD SPECIALISTS-
EASTCHESTER CANCER CENTER

Bronx, NY 10469

NEW YORK CANCER
AND BLOOD SPECIALISTS-
CENTRAL PARK HEMATOLOGY & ONCOLOGY

New York, NY 10028

UNIVERSITY MEDICAL CENTER

New Orleans, LA 70112

WASHINGTON UNIVERSITY

Saint Louis, MO 63110

UCLA

Santa Monica, CA 90404

City of Hope

Duarte, CA 91010

HIGHLANDS ONCOLOGY GROUP

Fayetteville, AK 72703

Arizona Oncology

Mesa, AZ 85206

Study of the Optimum Dose, Efficacy, Safety, and Pharmacokinetics of SM-88 in Patients With Prostate Cancer

Conditions: Prostate Cancer; Androgen-Independent Prostate Cancer;
Rising PSA; Castrate Resistant Non-Metastatic Prostate Cancer (CRNMPC)

Contacts and locations are listed below

Accumed Research
Associates

Garden City, NY 11530

Contact: Carmen Vicuna
Phone: (718) 732-4078
Email: cvicuna@nycancer.com

Eastchester Center
for cancer care

The Bronx, NY 10469

Contact: Carmen Vicuna
Phone: (718) 732-4078
Email: cvicuna@nycancer.com

Advancemed Research

Lawrenceville, NJ 08648

Contact: Jenna Spatz
Phone: (609) 895-0735
Email: jspatz@advancemed.info

Manhattan Medical
Research Practice

New York, NY 10016

Contact: Carmen Vicuna
Phone: (718) 732-4078
Email: cvicuna@nycancer.com

MIDLANTIC UROLOGY

Bala-Cynwyd, Pennsylvania, 19004

Contact: Cheryl A Zinar
Phone: (610) 667-0458

Interested in a Clinical Trial?